<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630004</url>
  </required_header>
  <id_info>
    <org_study_id>JAN13004-30</org_study_id>
    <nct_id>NCT02630004</nct_id>
  </id_info>
  <brief_title>Melatonin Oral Gel for Oral Mucositis in Patients With Head and Neck Cancer Undergoing Chemoradiation</brief_title>
  <acronym>MUCOMEL</acronym>
  <official_title>Phase IB-II Clinical Trial of Melatonin Oral Gel for the Prevention and Treatment of Oral Mucositis in Patients With Head and Neck Cancer Undergoing Chemoradiation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spherium Biomed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Català d'Oncologia L'Hospitalet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari de la Vall de Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Català d'Oncologia ICO Girona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Català d'Oncologia ICO Badalona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Miguel Servet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Marqués de Valdecilla</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen de la Victoria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Carlos, Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinico Universitario de Santiago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spherium Biomed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the efficacy of melatonin oral gel compared to
      placebo in the prevention and treatment of oral mucositis in patients with head and neck
      cancer undergoing concurrent chemoradiation.

      Other objectives are to assess the Quality of Life (QoL), to evaluate the safety and
      tolerability and to assess the pharmacokinetic profile of melatonin oral gel administration,
      in all cases compared to placebo in patients with head and neck cancer and oral mucositis
      secondary to concurrent chemoradiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a prospective, randomized, double blind and placebo-controlled
      study.

      Eligible patients with head and neck cancer undergoing chemoradiation will be randomized
      assigned at one-to-one ratio to receive

        -  Group A: melatonin oral gel 3%

        -  Group B: placebo

      All patients will receive standard symptomatic treatment for oral mucositis along the study
      according to routine clinical practice of the hospital.

      A full PK and safety assessment will be carried out in the first 24 patients included in the
      study (PK subgroup).

      All patients will take melatonin oral gel 3% or placebo oral gel from two to three days
      before start of systemic treatment until one to four weeks after completion of radiotherapy.
      In the case of concurrent chemotherapy with cisplatin, patients will remain on study from the
      first day of chemoradiotherapy during 19 weeks (seven on chemoradiotherapy treatment, a
      maximum of four weeks after completion of radiotherapy and eight more weeks on observation).
      In the case of patients receiving cetuximab, since the first infusion of cetuximab will be
      administered one week before the first day of radiation, the patients will remain on study
      during 20 weeks (eight weeks on chemoradiotherapy, a maximum of four weeks after completion
      of radiotherapy and eight more weeks on observation). Investigators should take into account
      that the minimum duration of the melatonin oral gel 3% treatment would be 8 weeks for
      patients treated with cisplatin and 9 weeks for patients treated with cetuximab.

      Patients with oral mucositis improved to grade 1 (based on RTOG) until one to four weeks
      after the end of chemoradiation may stop melatonin oral gel 3% or placebo treatments.
      Patients with grade ≥ 2 oral mucositis at this time-point (four weeks after the end of
      chemoradiation) will stop treatment per protocol (melatonin or placebo) and will continue
      with standard treatments and under observation until the last safety visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">December 22, 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number (percentage) of patients who develop severe oral mucositis (grade 3-4 according to the RTOG scale)</measure>
    <time_frame>up to 19-20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number (percentage) of patients who develop severe oral mucositis (grade 3-4 according to NCI-CTCAE)</measure>
    <time_frame>up to 19-20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with mucositis of any grade according to the RTOG scale</measure>
    <time_frame>up to 19-20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with grade 3-4 mucositis according to the RTOG scale</measure>
    <time_frame>up to 19-20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of grade 3-4 mucositis according to the RTOG scale from starting systemic antineoplastic treatment</measure>
    <time_frame>up to 19-20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EORTC QLQ-C30 and EORTC QLQ-H&amp;N35 scores at 4w after RT start</measure>
    <time_frame>up to 4-5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EORTC QLQ-C30 and EORTC QLQ-H&amp;N35 scores at one week after completion of RT</measure>
    <time_frame>up to 8-9 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EORTC QLQ-C30 and EORTC QLQ-H&amp;N35 scores at 3 months after completion of RT or before surgery - if it is required post-chemoradiation due persistent or recurrent disease</measure>
    <time_frame>up to 19-20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ECOG-Performance status score at different time points along the study</measure>
    <time_frame>up to 19-20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number (percentage) of patients with grade 1-4 NCI-CTCAE adverse events related to IMP (melatonin oral gel 3%)</measure>
    <time_frame>up to 19-20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number (percentage) of patients who develop cisplatin or cetuximab-associated grade 1-4 adverse events according to the NCI-CTCAE scale</measure>
    <time_frame>up to 19-20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number (percentage) of patients who develop radiation-associated adverse events different from oral mucositis according to the RTOG scale</measure>
    <time_frame>up to 19-20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics evaluation [Cmax]</measure>
    <time_frame>up to 11-12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics evaluation [Tmax]</measure>
    <time_frame>up to 11-12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics evaluation [AUC]</measure>
    <time_frame>up to 11-12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics evaluation [T1/2]</measure>
    <time_frame>up to 11-12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics evaluation [Vd]</measure>
    <time_frame>up to 11-12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics evaluation [Clearance]</measure>
    <time_frame>up to 11-12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in oral pain intensity measured by VAS at different time points along the study.</measure>
    <time_frame>two times a week up to 19-20 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number (percentage) of patients who need minor or major opioids</measure>
    <time_frame>up to 19-20 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number (percentage) of patients who need special procedures on nutritional status (feeding tube, jejunostomy, gastrostomy)</measure>
    <time_frame>up to 19-20 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Radiotherapy treatment breaks (cause)</measure>
    <time_frame>up to 8-10 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Radiotherapy treatment breaks (number of days)</measure>
    <time_frame>up to 8-10 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total dose and intensity of radiotherapy: Total Gy;</measure>
    <time_frame>up to 8-10 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total dose and intensity of radiotherapy: Gy/week;</measure>
    <time_frame>up to 8-10 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total dose and intensity of radiotherapy: Gy/day</measure>
    <time_frame>up to 8-10 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Milligrams of systemic antineoplastic treatment administered (dose intensity: mg/m2/week)</measure>
    <time_frame>up to 8-10 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number (percentage) of patients with complete response using the RECIST 1.1 criteria</measure>
    <time_frame>2 months after completion of radiotherapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number (percentage) of patients with partial response using the RECIST 1.1 criteria</measure>
    <time_frame>2 months after completion of radiotherapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number (percentage) of patients with stable disease using the RECIST 1.1 criteria</measure>
    <time_frame>2 months after completion of radiotherapy</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number (percentage) of patients with progression disease using the RECIST 1.1 criteria</measure>
    <time_frame>2 months after completion of radiotherapy</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin oral gel 3%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin oral gel 3%</intervention_name>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral gel</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients 18 years or over.

          2. Patients who gave written informed consent.

          3. Life expectancy ≥ 3 months.

          4. Subjects willing to comply with treatment and follow-up.

          5. Histologically confirmed diagnosis of non-metastatic TNM-2010 stage III-IV squamous
             cell carcinoma of the following sites:

               -  oral cavity

               -  oropharynx

               -  or any Head and Neck site with lymph nodes at cervical level II.

             Or histologically confirmed carcinoma of the nasopharynx (differentiated squamous cell
             carcinoma or NonKeratinizing carcinoma or undifferentiated carcinoma) found eligible
             for chemoradiation with or without neoadjuvant chemotherapy.

          6. Patients who have a treatment plan based on systemic treatment (cisplatin or
             cetuximab) concurrent with radiation with curative intent. Patients may have received
             up to 3 cycles of neoadjuvant chemotherapy if local adverse events related to this
             treatment are fully resolved before study entry. Patients with a plan of postoperative
             chemoradiation may be included only if the primary tumour is located in the oral
             cavity.

          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.

          8. Adequate baseline organ function (hematologic, liver, renal, nutritional and
             metabolic):

               -  Haematology:

                    -  Absolute neutrophil count (ANC) ≥1.5 x 109/L

                    -  Haemoglobin ≥ 10 g/dL

                    -  Platelets ≥ 100,000 x 109/L

               -  Hepatic:

                    -  Total bilirubin ≤ 2 X (Upper limit normal) ULN

                    -  Alanine amino transferase (ALT) and Asparatate aminotransferase (AST) ≤5 x
                       ULN

               -  Renal:

                    -  For patients who will receive cisplatin: Serum creatinine ≤ ULN or, if &gt; ULN
                       calculated creatinine clearance (ClCR) ≥ 60 mL/min.

                    -  For patients who will receive cetuximab: Serum creatinine &lt;2.0 mg/dl.

               -  Nutritional and metabolic:

                    -  Albumin &gt; 3.0 mg/dl

                    -  Magnesium &gt; lower limit normal (LLN) for patients who will receive cetuximab

        Exclusion Criteria:

          1. Patients with blistering disease.

          2. Patients who require feeding with either nasogastric tube, gastrostomy or jejunostomy
             at study entry

          3. Patients whose radiotherapy treatment planned dose is lower than 66 Gy

          4. Patients being receiving another investigational agent because of participation in
             another therapeutic trial

          5. Patients treated with fluvoxamine, estrogens, cimetidine, 5- and 8 methoxypsoralen
             and/or carbamazepine

          6. Active viral, bacterial or fungal infections of the mouth in the last 14 days (i.e.
             stomatitis related to herpes virus or candida)

          7. Pregnancy or lactation

          8. Known allergy to melatonin

          9. Prior radiotherapy of the head and neck

         10. Patients with a treatment plan consisting of chemoradiation followed by further
             chemotherapy

         11. Patients with a diagnostics of a synchronic neoplasia except for non-melanoma skin
             cancer curable with local treatment or in situ cervix carcinoma

         12. Any investigational agent within 30 days prior to inclusion

         13. Male or female of childbearing age who do not agree with taking adequate contraceptive
             precautions, i.e. use contraception double barrier (e.g. diaphragm plus condoms) or
             abstinence during the course of the study and for 2 months after the last
             administration of the study drug for women and 1 month for men

         14. Psychological, geographical, familial or sociological conditions that potentially
             prevent compliance with the study protocol and follow-up schedule according to
             investigator criteria. These conditions should be discussed with the patient before
             inclusion in the trial.

         15. Any other medical condition that would make the patient inappropiate for study
             participation according to the Investigator's judgement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alicia Lozano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Català d'Oncologia L'Hospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Català d'Oncologia ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia L'Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia Girona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Carlos, Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mucositis</keyword>
  <keyword>Head and Neck cancer</keyword>
  <keyword>Chemoradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

